Current drug design efforts primarily aim to target ZIKV proteins with enzymatic activities that are essential for virus replication, such as NS3 and NS5, while progress towards a ZIKV vaccine has been challenging due to the potential risk of neurological side effects and antibody-dependent enhancement of infection, a phenomenon that is best-characterized for DENV infection [23,24,25,26]. The gene discussed is KRAS; the disease is infection.